Good morning, everybody. It's a beautiful spring day here in Boston, and we have a pretty optimistic report that we're going to give you. Owen described our views of the business environment and the current challenges that are associated with the constant dynamic changes in trade relationships and government efficiency. My comments this morning will address what we're seeing in our results and our client interactions. Our client purchase cycle may be a lagging indicator, but based on the first quarter leasing results, both in our current pipeline of transactions under negotiation, and our funnel of possible additional activity, we've seen very little impact on our 2025 plan, which calls for about 4 million square feet of leasing, but more importantly, including about 3 million square feet of leasing on vacant space and known 2025 expirations, which is where our focus is our leased square footage. During the first quarter, we executed just over 1.1 million square feet, which is almost 35% more than our seasonal Q1 average over the last 5 years. More importantly, the activity included 467,000 square feet of leases on vacant space, and 561,000 square feet of 2025 known expirations. This 1 million square feet of leasing activity on our near-term exposure, vacant space and 25 expirations will drive improvements to our occupancy over the next 12 to 18 months. Post 4 125, our current pool of leases in negotiation is 1.1 million square feet. It covers an additional 435,000 square feet of currently vacant space. 230,000 square feet of 25 expirations, 190,000 square feet of 26 and 27 expirations, which will lower our future exposure as well as our second lease at 725 [indiscernible] We have another 1.7 million square feet of active pipeline transactions which could cover an additional 1 million square feet of vacant space or 25 expirations. This would put us on our target for our full year '25 vacant and 2025 expiring lease guidance of about 3 million square feet. One of the inferences from Owen's comments would seem to be enhanced caution from clients as they navigate uncertainty. And we would be naive to think we won't see some impact, but speaking to you today, it has yet to be material. Let me give you a few examples of current client behavior. An existing Boston client with a recent return-to-work mandate believes it needs additional seats, but it's being measured in its approach and waiting until there is clarity of use before they commit to more space. In our Reston, Virginia portfolio, where we have an embedded base of defense and security clients, where those probably we would think have the most impact. We are seeing renewals and incremental additional space needs, not downsizing and canceled requirements. There is a government contractor in the market that wants to relocate a 50,000 to 60,000 square feet block of space to the town center and at the moment, we're unable to accommodate them. In Manhattan, we have 1 existing 11,000 square foot client to put its expansion plans on hold saying, we want to watch how the financial markets evolve in the same building, another 11,000 square foot client in the same industry is negotiating for an 11,000 square foot expansion. In the aggregate, these conversations are consistent with what we were hearing in January 90 days ago. As we discussed in January, an expiration of 350,000 square feet at 200 Fifth Avenue coupled with about 150,000 square feet of expirations in San Francisco CBD this quarter occupancy reduction to 86.9%, a 60 basis point decrease from last quarter. However, we executed a lease for 244,000 square feet of that now vacant space at 2005 and expect occupancy in late [indiscernible] and our pipeline of deal discussions covers more than 125,000 square feet of our San Francisco CBD vacancy. So we're staying pretty level. The least in-service portfolio stayed flat quarter-to-quarter at 89.4%. So our lease but not yet commenced square footage has grown to 250 basis points or over 1.2 million square feet over our occupied square footage. And we expect about 800,000 square feet to commence in '25 with almost all the rest in '26. We have a large pickup in our development leasing this quarter, notice page 15 of our supplemental, where we signed up another floor at 360 Park Avenue South, our second lease at 72512 signed during the second quarter, and we completed 162,000 square foot lease at 1050 Winter Street resulting in a jump from 50% to 62% pre-leased on our development pipeline. 1050 Winter Street was out of service, and we had previously terminated all of the leases in order to reposition it as a life science building. Long story short, a defense technology company that is currently occupying 40,000 square feet in the market approached us to lease the entire building for 15 years and we made the decision to pivot back to office. The building is 100% pre-leased and will be brought into service in Q3 '25. Office market conditions are consistent with our remarks last quarter, with a possible exception that conditions are even tighter in our Midtown New York City portfolio, the Back Bay of Boston and Reston, Virginia. What this means is that availability is sparse, rents are increasing and concessions remain constant. We completed 91,091 individual transactions this quarter, $300,000 in Boston, 420,000 in New York, 350,000 on the West Coast, and 80,000 square feet in Reston. The overall mark-to-market on cash basis was up about 5% with an increase in Boston, flat in New York and decreases on the West Coast and in Reston. Other than the new lease at 200 Fifth and at 1050 Winter, no other transaction exceeded 40,000 square feet. Our highlights in Boston this quarter were in the Urban Edge, where we did a 15-year lease at 1050 Winter and a 39,000-square foot lease at 180 CityPoint. Last quarter, I remarked that we were touring life science clients that had no lab infrastructure needs, while the first of these transactions was executed in the first quarter at 180 City Point. In addition, we are in lease negotiations with a second client for another 40,000 square feet at 180 CityPoint. These life science companies are looking exclusively for office space as they focus their capital on acquiring de-risk products that are in trials rather than pure drug discovery and therefore, don't need lab infrastructure. The economics of doing an office transaction on raw space even though the building was purpose-built lab infrastructure in it are far superior to a lab transaction given the elevated tenant improvements necessary to compete in the markets. These [indiscernible] hold in South San Francisco as well as Greater Boston. In Manhattan, in addition to the new client at 200 Fifth, we were able to do 3 separate 25,000 square foot client expansions at the General Motors Building, 599 Lexington Avenue and 250 West 55th Street. Our most significant Midtown availability today is at 510 Madison, and we are in lease negotiations on 4 full floors. Taking rents in our Midtown properties are up double digits relative to a year ago and concessions are flat to slightly lower. Our availability in Manhattan is concentrated at 350 Park Avenue South, demand is picking up, and there has been some improvement in small tech tenant inquiry. The most significant change in San Francisco over the last quarter has been the completion of some of the large transactions that were in the works. The total volume of leases in the market has settled at a lower level as there are fewer active large requirements, but there are lots of potential clients under 50,000 square feet working in the market today. Many of the traditional office users have continued to rationalize their space which has led to a little if any growth in the San Francisco CBD traditional demand so increasing -- incremental leasing is all about tenant relocations. We had 1 lawfirm move out at EC at the end of '24, and 2 others renew, but they contracted on a total of 5 floors or 125,000 square feet. Each of the 2 renewals had 1 floor of giveback. We've leased 120,000 square foot floor in our lease in lease discussions for another 125,000 square feet of vacant space. View space is in short supply, but spacing the lower sections of buildings is available and competitive. Our new amenity center, the Mosaic is a strong drop for new clients considering Embarcadero Center. 2024 was a terrific absorption year for the AI companies with more than 1 million square feet of positive absorption. We need to see this trend continue. AI is getting a disproportionate share of all venture investing and more than 65% of it is going to San Francisco-based companies, so the future bodes well. Before I conclude my remarks, I want to discuss tariffs as they relate to construction activities. We are currently bidding a multifamily project in Jersey City 290 Colt. To date, about 60% of the job has been bid and awarded, and we are inside of our hard cost estimates by a few percentage points. We've had one trade worthy award bid necessitated a tariff upcharge. The contract, including the tariff cost was still below our budgeted estimate for the subcontract, but it's going to add somewhere between 1.5% and 4% to that particular trade. Given the overall slowdown in new construction, there seems to be enough subcontractor interest to offset potential tariff increases. Remember that construction is a composition of labor, materials and profit. While there's certainly a positive outcome for [indiscernible] , it's too early to predict how U.S. tariff policy will impact our future development activity. And with that, I'll turn the call over to Mike.